skip to main content

Vanishing Metastases — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardGI CancersVanishing MetastasesSCE Medical Oncology

A 62-year-old man with CRC liver metastases has a pathological complete response (no viable tumour on resected specimen) after neoadjuvant FOLFOX + bevacizumab. His oncologist discusses the concept of 'vanishing metastases'. What is this and how is it managed?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Plan treatment using the pretreatment map and resect or ablate original sites

Radiologically vanishing liver metastases may retain viable tumour, so surgery is planned against the pretreatment map and original sites are resected or ablated where feasible. Plan treatment from postoperative MRI and ablate sites with residual diffusion restriction: post-treatment invisibility cannot reliably identify sterilised original sites. Plan treatment from immediate preoperative CT and resect visible sites: the pre-treatment map is needed because chemotherapy can make viable lesions disappear radiologically. Plan treatment from intraoperative ultrasound and resect palpable sites: intraoperative assessment may help but does not recover every vanished original lesion. Plan treatment from FDG-PET and ablate metabolically active sites: PET negativity does not establish pathological eradication.

Reference: Expert consensus on selection for resection of colorectal liver metastases (Published July 2013): https://pmc.ncbi.nlm.nih.gov/articles/PMC3719914/; NICE NG151 colorectal cancer: recommendations (Current NICE recommendations, accessed July 2026): https://www.nice.org.uk/guidance/ng151/chapter/Recommendations